Maravai LifeSciences Announces August 2023 Investor Conference Schedule
08/09/2023 - 04:15 PM
SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of August.
On August 16, 2023, at 2:00 p.m. PDT, Trey Martin, Chief Executive Officer, and Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the UBS MedTech, Tools, and Genomics Summit 2023, being held at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, California.
A live webcast of the presentation will be available to all interested parties on the Maravai LifeSciences Investor Relations website, under News & Events . An archived version of the webcast will also be available on the Maravai website following the completion of the event.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.
For more information about Maravai LifeSciences, visit www.maravai.com .
Maravai LifeSciences Holdings Inc
MRVI Rankings
#4968 Ranked by Stock Gains
MRVI Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Commercial Services, Miscellaneous Commercial Services
Country
US
City
San Diego
About MRVI
maravai lifesciences catalyzes the growth of successful, entrepreneurial life science companies by providing expertise, capital, processes and systems so that they can continue to serve scientists who are striving to improve human health. current maravai lifesciences portfolio companies provide enabling tools and services in the life sciences research and bioproduction industries that accelerate breakthrough discoveries in areas such as genomics, proteomics, and biotherapeutic development. maravai lifesciences was formed in march 2014 through a partnership with gtcr, a leading private equity firm. our mission is to build a transformative life sciences reagents company by acquiring outstanding businesses and accelerating their growth. since our founding, we have acquired four companies, each a leader in its market segment. vector laboratories has led the market for labeling and detection products used by researchers in immunohistochemistry, immunofluorescence and related techniques. tri
